题目：Research Progress on Heparin and its Biomedical Applications
报告人：Prof. Fuming Zhang (美国伦斯勒理工大学张福明教授)
Prof. Fuming Zhang is a Research Professor in Department of Chemical and Biological Engineering at Rensselaer Polytechnic Institute (RPI). He had worked as a faculty member in ZJUT for 8 years before he went to University of Leeds in UK for his PhD education. His current research areas include molecular interactions studies using surface plasmon resonance (SPR) spectroscopy, glycomics, and glycoengineering. He has published more than 230 papers in high impact journals such as Nature Nanotechnology, Nature Methods, Journal of the American Chemical Society (JACS), Angewandte Chemie, Journal of Clinical Investigation. The paper is cited more than 300 times. The H-index is about 40. In addition, He has made more than 100 international conference reports and published 4 monographs. Moreover, He also serves editorial board members for Journal of Biomedical Technology and Research，Journal of Biotechnology and Bioengineering， Current Drug Discovery Technologies and Journal of Bioanalytical Technique.
Heparin is a highly sulfated, complex polysaccharide and widely applied as clinical anticoagulant with more than 100 tons of heparin used annually. A projected global market for heparin is expected to reach approximately $16.3 billion by 2025. This seminar presents the progress of heparin related glycoengineering/glycomics/interactome studies, include: i) Enzymatic generation of highly anticoagulant from bovine intestinal heparin: we converted bovine intestinal heparin (BIH), which has a low anticoagulant activity, to USP heparin by the treatment with 6-O-sulfotransferases and/or 3-O-sulfotransferase; ii) Heavy heparin: A stable isotope-enriched, chemoenzymatically-synthesized, poly-component drug: in this work, we chemoenzymatically synthesized perdeuteroheparin from biosynthetically enriched heparosan precursor obtained from microbial culture in deuterated medium. Chemical de-N acetylation, chemical N-sulfation, enzymatic epimerization, and enzymatic sulfation with recombinant heparin biosynthetic enzymes afforded perdeuteroheparin comparable to pharmaceutical heparin. iii) Alzheimer’s disease related glycomics/interactome research; iv) Development of heparin based bionanomaterials.